Mavenclad
cladribine
Multiple Sclerosis
Date of authorisation:
Revision: 10
Last updated:
MedicineHumanAuthorised
EMEA-003069-PIP01-21 - paediatric investigation plan
Decision type: W: decision granting a waiver in all age groups for all conditions or indications
Therapeutic area: Oncology
PIP number: P/0512/2021
Route(s) of administration: All routes of administration
Pharmaceutical form(s):
All pharmaceutical forms
Decision date:
Last updated:
Compliance check: ✖
PIPHuman
Litak
cladribine
Leukemia, Hairy Cell
Date of authorisation:
Revision: 7
Last updated:
MedicineHumanAuthorised
Movectro
cladribine
Date of withdrawal:
Last updated:
MedicineHumanWithdrawn application